Editas Medicine, Inc. Common Stock (EDIT) is a publicly traded Healthcare sector company. As of November 17, 2026, EDIT trades at $1.91 with a market cap of $334.92M and a P/E ratio of -3.77. EDIT moved +1.93% today. Year to date, EDIT is -9.02%; over the trailing twelve months it is -28.27%. Its 52-week range spans $0.91 to $4.54. Analyst consensus is strong buy with an average price target of $5.20. Rallies surfaces EDIT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Editas reports EDIT-401 LDL-C reduction; Strive data expected in 2027: A single EDIT-401 dose produced greater than 90% mean LDL-C reduction in nonhuman primates, sustained for approximately 10 months. Editas expects initial Strive safety and tolerability data in the first quarter of 2027 and says its cash runway extends into the second half of 2028.
| Metric | Value |
|---|---|
| Price | $1.91 |
| Market Cap | $334.92M |
| P/E Ratio | -3.77 |
| EPS | $-0.69 |
| Dividend Yield | 0.00% |
| 52-Week High | $4.54 |
| 52-Week Low | $0.91 |
| Volume | 10.65K |
| Avg Volume | 0 |
| Revenue (TTM) | $47.01M |
| Net Income | $-73.95M |
| Gross Margin | 0.00% |
5 analysts cover EDIT: 0 strong buy, 4 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $5.20.